Literature DB >> 31853080

Why and where an HIV cure is needed and how it might be achieved.

Thumbi Ndung'u1,2,3, Joseph M McCune4, Steven G Deeks5.   

Abstract

Despite considerable global investment, only 60% of people who live with HIV currently receive antiretroviral therapy. The sustainability of current programmes remains unknown and key incidence rates are declining only modestly. Given the complexities and expenses associated with lifelong medication, developing an effective curative intervention is now a global priority. Here we review why and where a cure is needed, and how it might be achieved. We argue for expanding these efforts from resource-rich regions to sub-Saharan Africa and elsewhere: for any intervention to have an effect, region-specific biological, therapeutic and implementation issues must be addressed.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31853080      PMCID: PMC8052635          DOI: 10.1038/s41586-019-1841-8

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  129 in total

1.  Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression.

Authors:  José M Martinez-Navio; Sebastian P Fuchs; Shara N Pantry; William A Lauer; Natasha N Duggan; Brandon F Keele; Eva G Rakasz; Guangping Gao; Jeffrey D Lifson; Ronald C Desrosiers
Journal:  Immunity       Date:  2019-03-05       Impact factor: 31.745

2.  HIV-1 integration landscape during latent and active infection.

Authors:  Lillian B Cohn; Israel T Silva; Thiago Y Oliveira; Rafael A Rosales; Erica H Parrish; Gerald H Learn; Beatrice H Hahn; Julie L Czartoski; M Juliana McElrath; Clara Lehmann; Florian Klein; Marina Caskey; Bruce D Walker; Janet D Siliciano; Robert F Siliciano; Mila Jankovic; Michel C Nussenzweig
Journal:  Cell       Date:  2015-01-29       Impact factor: 41.582

3.  The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles.

Authors:  Gabriela M Webb; Shengbin Li; Gwantwa Mwakalundwa; Joy M Folkvord; Justin M Greene; Jason S Reed; Jeffery J Stanton; Alfred W Legasse; Theodore Hobbs; Lauren D Martin; Byung S Park; James B Whitney; Emily K Jeng; Hing C Wong; Douglas F Nixon; R Brad Jones; Elizabeth Connick; Pamela J Skinner; Jonah B Sacha
Journal:  Blood Adv       Date:  2018-01-23

4.  Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.

Authors:  Ling Xu; Amarendra Pegu; Ercole Rao; Nicole Doria-Rose; Jochen Beninga; Krisha McKee; Dana M Lord; Ronnie R Wei; Gejing Deng; Mark Louder; Stephen D Schmidt; Zachary Mankoff; Lan Wu; Mangaiarkarasi Asokan; Christian Beil; Christian Lange; Wulf Dirk Leuschner; Jochen Kruip; Rebecca Sendak; Young Do Kwon; Tongqing Zhou; Xuejun Chen; Robert T Bailer; Keyun Wang; Misook Choe; Lawrence J Tartaglia; Dan H Barouch; Sijy O'Dell; John-Paul Todd; Dennis R Burton; Mario Roederer; Mark Connors; Richard A Koup; Peter D Kwong; Zhi-Yong Yang; John R Mascola; Gary J Nabel
Journal:  Science       Date:  2017-09-20       Impact factor: 47.728

5.  Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.

Authors:  Julian H Elliott; James H McMahon; Christina C Chang; Sulggi A Lee; Wendy Hartogensis; Namandje Bumpus; Rada Savic; Janine Roney; Rebecca Hoh; Ajantha Solomon; Michael Piatak; Robert J Gorelick; Jeff Lifson; Peter Bacchetti; Steven G Deeks; Sharon R Lewin
Journal:  Lancet HIV       Date:  2015-11-17       Impact factor: 12.767

6.  Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.

Authors:  Joseph P Casazza; Kathryn A Bowman; Selorm Adzaku; Emily C Smith; Mary E Enama; Robert T Bailer; David A Price; Emma Gostick; Ingelise J Gordon; David R Ambrozak; Martha C Nason; Mario Roederer; Charla A Andrews; Frank M Maldarelli; Ann Wiegand; Mary F Kearney; Deborah Persaud; Carrie Ziemniak; Raphael Gottardo; Julie E Ledgerwood; Barney S Graham; Richard A Koup
Journal:  J Infect Dis       Date:  2013-03-12       Impact factor: 5.226

7.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

8.  Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals.

Authors:  Johanna Tauriainen; Lydia Scharf; Juliet Frederiksen; Ali Naji; Hans-Gustaf Ljunggren; Anders Sönnerborg; Ole Lund; Gustavo Reyes-Terán; Frederick M Hecht; Steven G Deeks; Michael R Betts; Marcus Buggert; Annika C Karlsson
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

9.  Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation.

Authors:  Mila Jankovic; Michel C Nussenzweig; Lillian B Cohn; Israel T da Silva; Renan Valieris; Amy S Huang; Julio C C Lorenzi; Yehuda Z Cohen; Joy A Pai; Allison L Butler; Marina Caskey
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

10.  Cross-sectional estimates revealed high HIV incidence in Botswana rural communities in the era of successful ART scale-up in 2013-2015.

Authors:  Sikhulile Moyo; Simani Gaseitsiwe; Terence Mohammed; Molly Pretorius Holme; Rui Wang; Kenanao Peggy Kotokwe; Corretah Boleo; Lucy Mupfumi; Etienne Kadima Yankinda; Unoda Chakalisa; Erik van Widenfelt; Tendani Gaolathe; Mompati O Mmalane; Scott Dryden-Peterson; Madisa Mine; Refeletswe Lebelonyane; Kara Bennett; Jean Leidner; Kathleen E Wirth; Eric Tchetgen Tchetgen; Kathleen Powis; Janet Moore; William A Clarke; Shahin Lockman; Joseph M Makhema; Max Essex; Vlad Novitsky
Journal:  PLoS One       Date:  2018-10-24       Impact factor: 3.240

View more
  38 in total

Review 1.  The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.

Authors:  Lillian B Cohn; Nicolas Chomont; Steven G Deeks
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

2.  Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivo.

Authors:  Francesco R Simonetti; Hao Zhang; Garshasb P Soroosh; Jiayi Duan; Kyle Rhodehouse; Alison L Hill; Subul A Beg; Kevin McCormick; Hayley E Raymond; Christopher L Nobles; John K Everett; Kyungyoon J Kwon; Jennifer A White; Jun Lai; Joseph B Margolick; Rebecca Hoh; Steven G Deeks; Frederic D Bushman; Janet D Siliciano; Robert F Siliciano
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

3.  Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy.

Authors:  Adrienne E Swanstrom; Taina T Immonen; Kelli Oswald; Cathi Pyle; James A Thomas; William J Bosche; Lorna Silipino; Michael Hull; Laura Newman; Vicky Coalter; Adam Wiles; Rodney Wiles; Jacob Kiser; David R Morcock; Rebecca Shoemaker; Randy Fast; Matthew W Breed; Joshua Kramer; Duncan Donohue; Tyler Malys; Christine M Fennessey; Charles M Trubey; Claire Deleage; Jacob D Estes; Jeffrey D Lifson; Brandon F Keele; Gregory Q Del Prete
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

4.  Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.

Authors:  Chris Y Chiu; Judy J Chang; Ashanti I Dantanarayana; Ajantha Solomon; Vanessa A Evans; Rachel Pascoe; Céline Gubser; Lydie Trautman; Rémi Fromentin; Nicolas Chomont; James H McMahon; Paul U Cameron; Thomas A Rasmussen; Sharon R Lewin
Journal:  J Immunol       Date:  2021-12-01       Impact factor: 5.422

Review 5.  The Impact of Antiretroviral Therapy on Neurocognitive Outcomes Among People Living with HIV in Low- and Middle-Income Countries (LMICs): A Systematic Review.

Authors:  Henry Ukachukwu Michael; Sasha Naidoo; Kofi Boamah Mensah; Suvira Ramlall; Frasia Oosthuizen
Journal:  AIDS Behav       Date:  2021-02

6.  An Update on Antiretroviral Therapy.

Authors:  Luis Menéndez-Arias; Samara Martín-Alonso; Estrella Frutos-Beltrán
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development.

Authors:  Paula Cannon; Aravind Asokan; Agnieszka Czechowicz; Paula Hammond; Donald B Kohn; Andre Lieber; Punam Malik; Peter Marks; Matthew Porteus; Els Verhoeyen; Drew Weissman; Irving Weissman; Hans-Peter Kiem
Journal:  Hum Gene Ther       Date:  2021-01       Impact factor: 5.695

8.  TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4+ T Cells.

Authors:  Siqin Duan; Xinfeng Xu; Jinshen Wang; Liwen Huang; Jie Peng; Tao Yu; Yang Zhou; Kui Cheng; Shuwen Liu
Journal:  J Virol       Date:  2021-08-10       Impact factor: 5.103

Review 9.  Ethics of HIV cure research: an unfinished agenda.

Authors:  Karine Dubé; John Kanazawa; Jeff Taylor; Lynda Dee; Nora Jones; Christopher Roebuck; Laurie Sylla; Michael Louella; Jan Kosmyna; David Kelly; Orbit Clanton; David Palm; Danielle M Campbell; Morénike Giwa Onaiwu; Hursch Patel; Samuel Ndukwe; Laney Henley; Mallory O Johnson; Parya Saberi; Brandon Brown; John A Sauceda; Jeremy Sugarman
Journal:  BMC Med Ethics       Date:  2021-06-30       Impact factor: 2.834

10.  TL1A-DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses.

Authors:  Bruna Oriol-Tordera; Alex Olvera; Clara Duran-Castells; Anuska Llano; Beatriz Mothe; Marta Massanella; Judith Dalmau; Carmela Ganoza; Jorge Sanchez; Maria Luz Calle; Bonaventura Clotet; Javier Martinez-Picado; Eugènia Negredo; Julià Blanco; Dennis Hartigan-O'Connor; Christian Brander; Marta Ruiz-Riol
Journal:  J Immunol       Date:  2020-11-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.